A randomized controlled trial of licarti
β
Jing Xu; Zhong-Yang Shen; Xin-Guo Chen; Qing Zhang; Hui-Jie Bian; Ping Zhu; Hui-
π
Article
π
2007
π
John Wiley and Sons
π
English
β 356 KB
π 1 views
Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([ 131 I]mAb HAb18G/CD147) was saf